Healthcare sector continues to gain momentum
Healthcare and pharmaceutical stocks moved more strongly into focus, while the technology sector showed a mixed performance.
European defense companies were under extreme pressure. The triggers included profit-taking as well as concerns surrounding the cancellation of the German F126 frigate program, which put Rheinmetall in particular under heavy pressure.
Realignments in the UMBRELLA Strategy
The UMBRELLA Strategy further adjusted its positioning over the past week. The remaining positions in Palantir Technologies and Microsoft were completely removed from the strategy. At the same time, the positions in Tesla and Rheinmetall were reduced.
Bayer, Johnson & Johnson, Revolution Medicines and IBM moved further into focus in this regard. This further strengthened the orientation toward healthcare stocks and biotechnology.
Technology mixed and positive
The technology sector showed a mixed picture. Apple moved largely downward, while IBM could benefit from the increasing demand for enterprise AI, hybrid cloud solutions, and the presentation of new nanochips.
Despite the reduction of individual growth stocks, Artificial Intelligence, cloud infrastructure, and digital transformation remain important long-term investment themes.
Healthcare sector continues to gain importance
The healthcare sector was once again among the stronger market segments. Eli Lilly benefited from a new approval in the field of CLL. Johnson & Johnson, that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended extending the approval of Tecvayli in combination with Daratumumab .
The focus on Bayer reflects the assessment that the current valuation could offer attractive long-term potential, supported by positive signals in the proceedings before the US Supreme Court, which could reduce the existing legal risk.
At the same time, Revolution Medicines strengthens the engagement in the field of innovative cancer research and next-generation biotechnology.
Defense under pressure
Rheinmetall recorded a significant price correction over the past week. The decline was primarily triggered by profit-taking and concerns related to the cancellation of the German F126 frigate program.
Conclusion
Over the past week, the UMBRELLA Strategy has further increased its focus on healthcare stocks and biotechnology, refined its technology orientation, and at the same time adhered to long-term structural growth themes.
